Want to see SG:9G2 full AI Analyst Report?
9G2 Stock Chart & Stats
S$0.03
>-S$0.01(-3.45%)
At close: 4:00 PM EDT
S$0.03
>-S$0.01(-3.45%)
Day’s Range― - ―
52-Week RangeS$0.03 - S$0.08
Previous CloseN/A
Volume50.00K
Average Volume (3M)247.96K
Market Cap
S$48.27M
Enterprise ValueS$100.88M
Total Cash (Recent Filing)S$2.48M
Total Debt (Recent Filing)S$58.62M
Price to Earnings (P/E)―
Beta-0.17
Next Earnings
Nov 03, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding1,724,092,500
10 Day Avg. Volume138,640
30 Day Avg. Volume247,960
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)0.55
Price to Sales (P/S)1.94
P/FCF Ratio-2.83
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA ~95% revenue increase demonstrates meaningful demand traction and faster scale. Over the next 2–6 months higher top-line can help absorb fixed costs, improve utilization of facilities and services, and create operational leverage that supports continued margin recovery if sustained.
High Gross MarginA structural gross margin near 92% implies high markup or low variable costs, meaning each incremental sale contributes heavily toward covering fixed overhead. If maintained, this durable advantage enables faster progress to break-even as revenue scales and supports reinvestment in services or capacity.
Improving Free Cash Flow TrendA ~91% improvement in free cash flow indicates better conversion of revenue into cash and early operating improvements. While still negative, the trajectory reduces immediate funding pressure, suggesting management actions or scale effects that can materially ease cash requirements within months if sustained.
Bears Say
Deep And Persistent LossesVery large net losses and persistently negative operating results signal entrenched unprofitability. These losses erode retained capital and require repeated external financing, making execution and funding the primary structural risks over the next several months until the company can convert strong gross profits into positive operating income.
Rising LeverageMeaningful and increasing leverage reduces financial flexibility and raises refinancing and interest expense risk. With operating losses and negative cash flow, a return to higher debt levels increases vulnerability to funding cost spikes and constrains strategic options during the next 2–6 months.
Consistent Cash BurnPersistent negative operating cash flow demonstrates ongoing cash burn and reliance on external funding. This structural cash deficit limits the company's ability to self-fund growth or absorb shocks, making near-term execution and liquidity management critical risks until operations become cash-positive.
Singapore Institute of Advanced Medicine Holdings Ltd. News
9G2 FAQ
What was Singapore Institute of Advanced Medicine Holdings Ltd.’s price range in the past 12 months?
Singapore Institute of Advanced Medicine Holdings Ltd. lowest share price was S$0.03 and its highest was S$0.08 in the past 12 months.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap?
Singapore Institute of Advanced Medicine Holdings Ltd.’s market cap is S$48.27M.
When is Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date?
Singapore Institute of Advanced Medicine Holdings Ltd.’s upcoming earnings report date is Nov 03, 2026 which is in 87 days.
How were Singapore Institute of Advanced Medicine Holdings Ltd.’s earnings last quarter?
Singapore Institute of Advanced Medicine Holdings Ltd. released its earnings results on May 14, 2026. The company reported -S$0.004 earnings per share for the quarter, missing the consensus estimate of N/A by -S$0.004.
Is Singapore Institute of Advanced Medicine Holdings Ltd. overvalued?
According to Wall Street analysts Singapore Institute of Advanced Medicine Holdings Ltd.’s price is currently Overvalued.
Does Singapore Institute of Advanced Medicine Holdings Ltd. pay dividends?
Singapore Institute of Advanced Medicine Holdings Ltd. does not currently pay dividends.
What is Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate?
Singapore Institute of Advanced Medicine Holdings Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Singapore Institute of Advanced Medicine Holdings Ltd. have?
Singapore Institute of Advanced Medicine Holdings Ltd. has 1,724,092,500 shares outstanding.
What happened to Singapore Institute of Advanced Medicine Holdings Ltd.’s price movement after its last earnings report?
Singapore Institute of Advanced Medicine Holdings Ltd. reported an EPS of -S$0.004 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -6.522%.
Which hedge fund is a major shareholder of Singapore Institute of Advanced Medicine Holdings Ltd.?
Currently, no hedge funds are holding shares in SG:9G2
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Singapore Institute of Advanced Medicine Holdings Ltd. Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Insider Transactions
Bought Shares
Worth S$1.4M over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-55.69%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-7.63%
Trailing 12-Months
Company Description
Singapore Institute of Advanced Medicine Holdings Ltd.
Singapore Institute of Advanced Medicine Holdings Ltd. operates as a holding company primarily focused on delivering healthcare services. Its operations include providing pharmaceutical products, surgical supplies, and medical laboratory services. The company was founded by Djeng Shih Kien on November 24, 2011, and is headquartered in Singapore.
Singapore Institute of Advanced Medicine Holdings Ltd. (9G2) Earnings & Revenues
Technical Analysis
Raffles Medical Group
―
Thomson Medical Group Ltd.
―
HC Surgical Specialists Ltd
―
ISEC Healthcare Ltd
―
OUE Lippo Healthcare Limited
―